2Q Earnings Quick Preview: Lg Commercial (ALNY ASND INSM INCY ONC)

Research evidence excerpt

2Q Earnings Quick Preview: Lg Commercial (ALNY ASND INSM INCY ONC)

USA | Biotechnology EquityJulyResearch12, 2026

KEY STOCKS FEATURED INCLUDE:2Q Earnings Quick Preview: Lg Commercial

TICKER RATING PRICE TARGET(ALNY ASND INSM INCY ONC)

ALNY HOLD $330.00

Within our larger, mid-cap biotech coverage (ALNY, ASND, INCY, INSM, ONC) ASND BUY $325.00

we're most closely watching earnings for INSM, ASND, ONC. Similar to last qtr, INCY HOLD $105.00

INSM Brinsupri is high on investor focus list. For ASND, we're encouraged by INSM BUY $160.00

Yorvipath's trajectory so far and looking fwd to strong start forms converting ONC BUY $380.00

to revs growth. For ONC, we upgraded and expect a Brukinsa beat. *Join our

Zoom call Mon 7/13 10am ET to discuss*

Exhibit 1 - Key Prints We're Watching KEY CHANGES INCLUDE:

Khurshid Biotech Coverage: Key Drugs Watch (Lg Commercial)

Company Drug Consensus 2Q JEFe 2Q % Diff Notes Consensus FY26 JEFe 2026 % Diff TICKER RATING PRICE TARGET

ALNY Amvuttra US $ 828 $ 868 5% Strong scripts data $ 3,498 $ 3,678 5%

ASND BUY $325.00 ($290.00)

ALNY Amvuttra WW $ 1,045 $ 1,076 3% -- $ 4,450 $ 4,539 2%

ASND Yorvipath US € 220 € 218 -1% Pull-throughconsistent ~1kof revsstartsfrom € 895 € 895 0% INCY HOLD $105.00 ($100.00)

ASND Yorvipath WW € 248 € 260 5% EUone-offbouncebacknegativefrom 1Q € 1,056 € 1,067 1% INSM BUY $160.00 ($175.00)

INCY Jakafi US $ 803 $ 801 0% -- $ 3,263 $ 3,262 0%

INCY Opzelura WW $ 241 $ 443 84% One-offplus GTN$246Mbenefitadd-back $ 820 $ 1,121 37%

INSM Brinsupri $ 277 $ 291 5% Patientest consistentbuild + Symphony $ 1,223 $ 1,250 2%

ONC Brukinsa US $ 838 $ 939 12% Strong scripts data $ 3,344 $ 3,650 9%

ONC Brukinsa WW $ 1,186 $ 1,328 12% -- $ 4,799 $ 5,171 8%

.

Source: Jefferies Research, VisibleAlpha